Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer
Phase 2
- Conditions
- Germline BRCA-mutated HER2-negative Breast Cancer
- Interventions
- Drug: Camrelizumab+Fluzoparib
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT05576389
- Locations
- 🇨🇳
Breast Cancer, Peking University People's Hospital, Beijing, Beijing, China
Effect of Butyrate Supplement on Rheumatoid Arthritis
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05576597
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
The Beijing Angle Closure Progression Study
Recruiting
- Conditions
- Angle-Closure Glaucoma
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 825
- Registration Number
- NCT05563623
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beeijing, China
The Efficacy of Preventive Regenerative Peripheral Nerve Interface(RPNI) Reconstruction in Amputees
Not Applicable
Recruiting
- Conditions
- Amputation Neuroma
- Interventions
- Procedure: preventive regenerative peripheral nerve interface reconstruction
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05554900
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML
Phase 1
Completed
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia
- Interventions
- Biological: LILRB4 STAR-T cells
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT05548088
- Locations
- 🇨🇳
Peking Unicersity People'S Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Adenocarcinoma of Esophagogastric Junction
- Interventions
- Drug: neoadjuvant Radiation plus SOX and PD-1 antibody
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT05505461
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Interleukin-2 on Active Dermatomyositis
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT05495321
- Locations
- 🇨🇳
Peking university people's hospital, Beijing, Beijing, China
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05495828
- Locations
- 🇨🇳
Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing, China
The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 228
- Registration Number
- NCT05494307
A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05491044
- Locations
- 🇨🇳
Department of Hematology, Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath